Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 108 clinical trials
None
Ibrutinib for the Treatment of COVID-19 in Patients Requiring Hospitalization

This phase Ib/II trial studies the side effects and best dose of ibrutinib and how well it works in treating patients with COVID-19 requiring hospitalization. Ibrutinib may help improve COVID-19

aplastic anemia
growth factor
ibrutinib
immunosuppression
neutrophil count
  • 0 views
  • 18 Sep, 2021
  • 1 location
None
Trial of Ibrutinib Combined With Nivolumab or Cetuximab to Treat Recurrent/Metastatic HNSCC

This is an open-label, randomized, phase II trial to test the efficacy of Ibrutinib in combination with either Nivolumab or Cetuximab in the treatment of recurrent and/or metastatic head an neck

growth factor
filgrastim
oropharyngeal
squamous cell carcinoma
neutrophil count
  • 0 views
  • 08 Sep, 2021
  • 1 location
None
A Study of Ibrutinib With Rituximab in People With Untreated Marginal Zone Lymphoma

The purpose of this study is to see if the combination of rituximab and ibrutinib can help people with marginal zone lymphoma who have not received treatment in the past. The study will also

measurable disease
rituximab
ct scan
gastric malt lymphoma
  • 36 views
  • 01 Oct, 2021
  • 12 locations
None
Efficacy of Carfilzomib in Combination With Ibrutinib in Waldenstr m's Macroglobulinemia

activity in WM and its low toxicity, Ibrutinib was approved for the treatment of WM by the European Medicines Agency (EMA). However, also Ibrutinib fails to induce CRs and the VGPR rate is 16% in relapsed

immunohistochemistry
dexamethasone
anemia
monoclonal antibodies
cold agglutinin
  • 0 views
  • 17 Sep, 2021
  • 11 locations
None
Obinutuzumab Ibrutinib and Venetoclax for the Treatment of Previously Untreated Stage II-IV Follicular Lymphoma

This phase II trial studies how well obinutuzumab, ibrutinib, and venetoclax work in treating patients with previously untreated stage II-IV follicular lymphoma. Immunotherapy with obinutuzumab

  • 0 views
  • 11 Mar, 2021
  • 1 location
None
Bruton's Tyrosine Kinase Inhibitor Ibrutinib as Maintenance Treatment in Elderly Patients With Primary CNS Lymphoma

one more chemotherapy agent). Patients with MRI documented response CR or PR will enter the study protocol maintenance phase which will include continous treatment with Ibrutinib 560 mg day

methotrexate
growth factor
rituximab
maintenance treatment
neutrophil count
  • 0 views
  • 29 Mar, 2021
  • 1 location
None
Ibrutinib Fludarabine Phosphate Cyclophosphamide and Obinutuzumab in Treating Patients With Chronic Lymphocytic Leukemia

This phase II trial studies how well ibrutinib, fludarabine phosphate, cyclophosphamide, and obinutuzumab work in treating patients with chronic lymphocytic leukemia. Ibrutinib may stop the

monoclonal antibody therapy
ibrutinib
monoclonal antibodies
gilbert's syndrome
beta human chorionic gonadotrophin
  • 0 views
  • 29 Jul, 2021
  • 1 location
None
Study of Ibrutinib in Combination With Bendamustine and Rituximab for Patients With Relapsed/Refractory Aggressive BCL

This is a phase 2 study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (ibrutinib), in combination with bendamustine and rituximab (BR) in subjects with previously treated aggressive B

indolent lymphoma
growth factor
gilbert's syndrome
b-cell lymphoma
chronic lymphocytic leukemia
  • 2 views
  • 22 Jan, 2021
  • 2 locations
None
Ibrutinib Bortezomib and Rituximab-CHOP for the Treatment of Elderly Patients With CD20+ DLBCL IPI 2

The ImbruVeRCHOP-Trials is an Investigator-initiated, single-arm, multi-center, prospective, open phase I/II trial to evaluate the efficacy and feasibility of Ibrutinib and Bortezomib in the

growth factor
prednisone
b-cell lymphoma
ejection fraction
follicular lymphoma
  • 4 views
  • 28 Jan, 2021
  • 2 locations
None
Ibrutinib in Preventing Acute Leukemia in Patients After Reduced-Intensity Conditioning and Stem Cell Transplant

This phase II trial studies how well ibrutinib works in preventing acute leukemia in patients after reduced-intensity conditioning and stem cell transplant. Ibrutinib may stop the growth of

gilbert's syndrome
tacrolimus
fludarabine
leukemia
myeloablative conditioning
  • 54 views
  • 24 Jan, 2021
  • 1 location